|
Apr 11
|
Exact Sciences Announces Debt Exchange Transaction and Private Placement of Convertible Senior Notes
|
|
Apr 10
|
Exact Sciences (EXAS) Stock Moves -0.89%: What You Should Know
|
|
Apr 10
|
3 Buy-Rated Stocks Flexing Relative Strength
|
|
Apr 10
|
Search for Cancer Blood Test Continues Despite Illumina-Grail Deal’s Failure
|
|
Apr 10
|
ZTS, EXAS, AZN: Which Biotech Stock Is the Better Buy?
|
|
Apr 9
|
11 Best Biotech ETFs To Buy
|
|
Apr 8
|
Exact Sciences to Present Late-Breaking Data from ASCEND-2 Study Validating Its Investigational Multi-Cancer Early Detection Test at AACR Annual Meeting 2024
|
|
Apr 8
|
Sorry, but Blood Tests Won’t Replace Stool Samples or Colonoscopies Yet
|
|
Apr 8
|
Exact Sciences Schedules First Quarter 2024 Earnings Call
|
|
Apr 5
|
The 3 Best Cathie Wood Stocks to Buy in April 2024
|
|
Apr 5
|
Freenome’s colorectal cancer blood test data underwhelm analysts
|
|
Apr 4
|
1 Beaten-Down Cathie Wood Stock to Buy and Hold
|
|
Apr 4
|
Exact Sciences to Provide Mayo Clinic Patients with Individualized Cancer Tumor Information to Inform Treatment
|
|
Apr 3
|
Exact Sciences' (EXAS) Oncoguard Esophagus Test Looks Promising
|
|
Apr 2
|
Exact Sciences, A Cathie Wood Stock, Surges As Rival Colon Cancer Test Pales
|
|
Mar 29
|
Exact Sciences, Mayo Clinic share early data on esophageal cancer test
|
|
Mar 28
|
Ligand (LGND) Down 15.5% Since Last Earnings Report: Can It Rebound?
|
|
Mar 28
|
Exact Sciences Advances Development of Non-Endoscopic Oncoguard® Esophagus Test to Screen for Esophageal Cancer and Pre-Cancer
|
|
Mar 27
|
Exact Sciences Named 2024 Gallup Exceptional Workplace Award Winner
|
|
Mar 26
|
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
|